Form 8-K - Current report:
SEC Accession No. 0001213900-20-015132
Filing Date
2020-06-17
Accepted
2020-06-16 19:13:08
Documents
15
Period of Report
2020-06-11
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea123112-8k_lanternpharma.htm 8-K 21177
2 AMENDMENT TO CERTIFICATE OF INCORPORATION ea123112ex3-1iv_lantern.htm EX-3.1.IV 1963
3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ea123112ex3-1v_lantern.htm EX-3.1.V 4178
4 PRESS RELEASE ANNOUNCING THE CLOSING OF THE INITIAL PUBLIC OFFERING ea123112ex99-1_lantern.htm EX-99.1 9151
5 GRAPHIC ex99-1_001.jpg GRAPHIC 14703
6 GRAPHIC ex3-1iv_001.jpg GRAPHIC 114827
7 GRAPHIC ex3-1iv_002.jpg GRAPHIC 313910
8 GRAPHIC ex3-1iv_003.jpg GRAPHIC 65150
9 GRAPHIC ex3-1v_001.jpg GRAPHIC 112144
10 GRAPHIC ex3-1v_002.jpg GRAPHIC 235217
11 GRAPHIC ex3-1v_003.jpg GRAPHIC 428398
12 GRAPHIC ex3-1v_004.jpg GRAPHIC 380207
13 GRAPHIC ex3-1v_005.jpg GRAPHIC 384080
14 GRAPHIC ex3-1v_006.jpg GRAPHIC 173925
15 GRAPHIC ex3-1v_007.jpg GRAPHIC 96316
  Complete submission text file 0001213900-20-015132.txt   3231595
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39318 | Film No.: 20967697
SIC: 2834 Pharmaceutical Preparations